Clinical effects of “pioglitazone”, an insulin sensitizing drug, on psoriasis vulgaris and its co-morbidities, a double blinded randomized controlled trialx1

References

• Gottlieb AB, Chao C, Dann F. Psoriasis comorbidities. J Dermatolog Treat. 2008;19:5–21
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Sterry W. Psoriasis – a systemic inflammatory disorder: clinic, pathogenesis and therapeutic perspectives. J Dtsch Dermatol Ges. 2009;7:946–52
   PubMed Web of Science ®Google Scholar
• Derosa G, Salvadeo SA. Pioglitazone and rosiglitazone: effects of treatment with a thiazolidinedione on lipids and non conventional cardiovascular risk factors. Curr Clin Pharmacol. 2008;3:77–84
   PubMedGoogle Scholar
• Ellis CN, Varani J, Fisher GJ, et al. Troglitazone improves psoriasis and normalizes models of proliferative skin disease: ligands for peroxisome proliferator-activated receptor-gamma inhibit keratinocyte proliferation. Arch Dermatol. 2000;136:609–16
   PubMed Web of Science ®Google Scholar
• Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors in inflammation control. J Endocrinol. 2001;169:453–9
   PubMed Web of Science ®Google Scholar
• Kuenzli S, Saurat JH. Peroxisome proliferator-activated receptors in cutaneous biology. Br J Dermatol. 2003;149:229–36
   PubMed Web of Science ®Google Scholar
• Bolten CW, Blanner PM, McDonald WG, et al. Insulin sensitizing pharmacology of thiazolidinediones correlates with mitochondrial gene expression rather than activation of PPAR gamma. Gene Regul Syst Biol. 2007;1:73–82
   Google Scholar
• Luconi M, Cantini G, Serio M. Peroxisome proliferator-activated receptor gamma (PPARgamma): is the genomic activity the only answer? Steroids 2010;75:585–94
   PubMed Web of Science ®Google Scholar
• Reich K, Mrowietz U. Treatment goals in psoriasis. J Dtsch Dermatol Ges. 2007;5:566–74
   PubMedGoogle Scholar
• Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303:1–10
   PubMed Web of Science ®Google Scholar
• Gilmour D, Sykes AJ. Westergren and Wintrobe methods of estimating ESR compared. Br Med J 1951;2:1496–7
   PubMedGoogle Scholar
• Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.0.0 [February 2008]. The Cochrane Collaboration [Internet]. Available from: www.cochrane.org. Accessed January 1, 2009
   Google Scholar
• Schulz KF, Altman DG, Moher D. CONSORT statement: updated guidelines for reporting parallel group randomised trials. BMJ. 2010;340:c332
   PubMed Web of Science ®Google Scholar
• Itoh S, Kanazuka A, Akimoto T. Combined treatment with ursodeoxycholic acid and pioglitazone in a patient with NASH associated with type 2 diabetes and psoriasis. Dig Dis Sci. 2003;48:2182–6
   Google Scholar
• Robertshaw H, Friedmann PS. Pioglitazone: a promising therapy for psoriasis. Br J Dermatol. 2005;152:189–91
   PubMed Web of Science ®Google Scholar
• Shafiq N, Malhotra S, Pandhi P, et al. Pilot trial: pioglitazone versus placebo in patients with plaque psoriasis (the P6). Int J Dermatol. 2005;44:328–33
   PubMed Web of Science ®Google Scholar
• Ohtsuka T. The relation between high-sensitivity C-reactive protein and maximum body mass index in patients with psoriasis. Br J Dermatol. 2008;158:1141–3
   PubMed Web of Science ®Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leucocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol. 2009;24:789–96
   Google Scholar
• Coimbra S, Oliveira H, Reis F, et al. Psoriasis therapy and cardiovascular risk factors: a 12-week follow-up study. Am J Clin Dermatol. 2010;11:423–32
   PubMed Web of Science ®Google Scholar
• Zaher H, Shaarawy E, Kadry D, et al. Circulating adipokines in a sample of egyptian patients with psoriasis. Egypt J Derm Androl. 2010;30:33–42
   Google Scholar
• Ahmed EF, Seliem MK, El-kamel MF, et al. Prevalence of metabolic syndrome in Egyptian patients with psoriasis. Egypt J Derm Androl. 2009;29:91–100
   Google Scholar
• Rajagopalan R, Iyer S, Khan M. Effect of pioglitazone on metabolic syndrome risk factors: results of double-blind, multicenter, randomized clinical trials. Curr Med Res Opin. 2005;21:163–72
   PubMed Web of Science ®Google Scholar
• Szapary PO, Bloedon LT, Samaha FF, et al. Effects of pioglitazone on lipoproteins, inflammatory |markers, and adipokines in non-diabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol. 2006;26:182–8
   PubMed Web of Science ®Google Scholar
• Kato T, Sawai Y, Kanayama H, et al. Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes 2009;117:593–9
   PubMed Web of Science ®Google Scholar
• El-Ramly A, Eltawdy A, El-Shahat NA, et al. Psoriasis and insulin resistance. Med J Cairo Univ. 2010;78:565–71
   Google Scholar
• Channual J, Wu JJ, Dann FJ. Effects of tumor necrosis factor-alpha blockade on metabolic syndrome components in psoriasis and psoriatic arthritis and additional lessons learned from rheumatoid arthritis. Dermatol Ther. 2009;22:61–73
   PubMed Web of Science ®Google Scholar
• Karadag AS, Ertugrul DT, Kalkan G, et al. The effect of acitretin treatment on insulin resistance, retinol-binding protein-4, leptin, and adiponectin in psoriasis vulgaris: a noncontrolled study. Dermatology. 2013;227:103–8
   PubMed Web of Science ®Google Scholar